Navigation Links
John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
Date:3/5/2008

ROCHESTER, N.Y., March 5 /PRNewswire/ -- Vaccinex, Inc. announced today that Dr. John E. Leonard has joined its Scientific Advisory Board, and will be actively involved in the strategic planning and execution of the company's therapeutic antibody development programs.

Dr. Leonard has over 20 years of experience at Idec and Biogen Idec, having held Senior Director level positions in Regulatory Affairs, Quality, Project Management and Product Development, and Vice President level positions in Quality, Product Development and Program Management.

Dr. Maurice Zauderer, Vaccinex's President and CEO, remarked: "As we advance our lead therapeutic antibody candidates into pre-clinical and clinical development, we are delighted that John has agreed to join our SAB and take an active role in advising the company on our technical development plans and pipeline strategies. With his extensive background in antibody drug development, and his first-hand experience in the development of Rituxan(R), Zevalin(R) and most recently Tysabri(R), he will be an invaluable resource to our in-house development team."

"I am very pleased to join Vaccinex's Scientific Advisory Board. With the company's novel ActivMAb(R) antibody discovery technology and its emerging pipeline of lead antibody candidates, I think Vaccinex is well positioned to advance the development of several innovative therapies in the areas of cancer, autoimmune disease, and inflammation," said Dr. Leonard.

Dr. Leonard received his BS in Chemistry and MS in Biochemistry from California State University, Long Beach, and his Ph.D. in Biochemistry from the University of California, Riverside. He is a retired U.S. Army Colonel serving most recently in the Medical Services Corps.

About Vaccinex

Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies and other biologics to treat a variety of serious illnesses, including autoimmune disease, inflammation, multiple sclerosis, and cancer. The company's patented ActivMAb(R) technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Vaccinex, on its own or with its partners, has advanced several antibodies from discovery and lead validation into IND-directed pre-clinical drug development. The company is headquartered in Rochester, NY, USA. For more information, please visit http://www.vaccinex.com.

Additional Information

Rituxan(R) and Zevalin(R) are registered trademarks of Biogen Idec. Tysabri(R) is a registered trademark of Elan Pharmaceuticals.

Press Contact

Raymond E. Watkins, Vice President of Operations & Officer

Vaccinex, Inc.

+1.585.271.2700 Ext. 105

E-mail: rwatkins@vaccinex.com


'/>"/>
SOURCE Vaccinex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors
2. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
3. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
4. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
5. WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
6. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
7. TopSpin Medical Appoints Cindy Setum, Ph.D., Vice President Clinical Affairs
8. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
9. Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility
10. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
11. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... ... the VTX-1 Liquid Biopsy System , a fully automated benchtop system for ... technology. The VTX-1 is being launched at the Molecular Medicine Tri Conference (Tri-Con) ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... announce that Dr. Trevor Heritage has joined its executive team to lead the ... designed to provide insights to help improve the diagnosis and treatment of cancer. ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... division, Treximo will pair its $200M operational capacity with its strategic internal ... management in areas affecting quality and operational management. With office locations ...
(Date:2/21/2017)... ... February 21, 2017 , ... Creation Technologies, a private company ... equipment manufacturers (OEMs) , today announced it has received the ‘Highest Overall Customer ... in its category of electronics manufacturing services (EMS) providers with annual revenues over ...
Breaking Biology Technology:
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... The global synthetic-biology market ... billion by 2021, growing at a compound annual growth rate ... overview of the global markets for synthetic biology. - Analyses ... 2016, and projections of compound annual growth rates (CAGRs) through ...
Breaking Biology News(10 mins):